Identifying gene signatures contributing to progression after chemotherapy in DLBCL patients
Lymphoma is a cancer that begins in the lymphocyte cells of the immune system. There are over 60 different types, broadly grouped into Hodgkin lymphomas and non-Hodgkin lymphomas. Diffuse Large B-Cell Lymphoma (DLBCL) is the most common type of Non-Hodgkin lymphoma. The primary treatment for DLBCL...
Main Author: | Vijay, Varsheni |
---|---|
Other Authors: | Li Yinghui |
Format: | Student Research Poster |
Language: | English |
Published: |
Nanyang Technological University
2023
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/170727 |
Similar Items
-
Sustained activation of non-canonical NF-κB signalling drives glycolytic reprogramming in doxorubicin-resistant DLBCL
by: Lim, Shen Kiat, et al.
Published: (2023) -
Contribution of metabolic reprogramming to genome instability in cancer progression
by: Woo, Ren He
Published: (2015) -
Defining gene signature underlying impaired hippocampal neurogenesis in triple transgenic Alzheimer’s disease mice
by: Ng, Yi Lin
Published: (2016) -
Identifying genes involved in neuronal differentiation of oln-93 oligodendroglia cells.
by: Huang, Yi Xia.
Published: (2010) -
Molecular characterisation of the effects of classical chemotherapy on Candida albicans and systemic candidiasis
by: Teoh, Flora Poh Leng
Published: (2017)